Fresenius SE & Co. KGaA

Fresenius is a health care group providing products and services for dialysis, hospitals and the medical care of patients at home. In addition, Fresenius focuses on hospital operation, as well as on engineering and services for hospitals and other health care facilities. Approximately 170,000 employees have dedicated themselves to the service of health in about 100 countries worldwide.

Fresenius Group in Figures

million €	2012 US GAAP	2011 US GAAP	2010 US GAAP	2009 US GAAP	2008 US GAAP
Results of operations
Sales	19,290	16,3611	15,972	14,164	12,336
EBIT	3,0752	2,563	2,418	2,054	1,7273
Net income2	938	770	660	514	450
Depreciation and amortization (before special items)4	776	674	639	562	783
Earnings per share in € (before special items)4	5.42	473	4.08	3.18	2.85
Balance sheet
Operating cash flow	2,438	1,689	1,911	1,553	1,074
Operating cash flow in % of sales	12.6 %	10.3%	12.0%	11.0%	8.7%
Total assets	30,664	26,321	23,577	20,882	20,544
Non-current assets	22,551	19,170	17,142	15,519	15,466
Equity5	12,758	10,577	8,844	7,491	6,943
Net debt	10,143	9,164	8,015	7,879	8,417
Net debt / EBITDA	2.66	2.8	2.6	3.0	3.6
Equity ratio5	42%	40%	38%	36%	34%
Investments8	4,179	2,395	1,402	931	4,617
Profitability
EBIT margin	15.9%2	15.7%	15.1%	14.5%	14.0%3
Return on equity after taxes (ROE)4	12.3%	12.9%	13.3%	12.1%	10.5%7
Return on operating assests (ROOA)	11.0%2	10.9%	11.6%	10.5%	9.8%7
Return on invested capital (ROIC)	9.0%2	8.8%	8.9%	8.2%	7.3%7
Dividend
per share in €	1.109	0.95	0.86	0.75	0.70
Employees (Dec 31)
	169,324	149,351	137,552	130,510	114,181

¹ 2011 sales were adjusted by - € 161 million according to a U.S. GAAP accounting change. This solely relates to Fresenius Medical Care North America.

² 2012 adjusted for one-time costs (€ 6 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG as well as for other one-time costs (€ 86 million) at Fresenius Medical Care.

³ 2008 adjusted for special items relating to the acquisition of Fresenius Kabi USA (formerly APP Pharmaceuticals)

⁴ Net income attributable to shareholders of Fresenius SE & Co. KGaA, 2012 adjusted for a non-taxable investment gain (€ 34 million) and other one-time costs (€ 17 million) at Fresenius Medical Care as well as for one-time costs (€ 29 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG.
2009 – 2011 adjusted for the effects of mark-to-market accounting of the MEB and the CVR.
2008 adjusted for special items relating to the acquisition of Fresenius Kabi USA (formerly APP Pharmaceuticals)

⁵ Including noncontrolling interest

⁶ Before special items

⁷ Pro-forma Fresenius Kabi USA (formerly APP Pharmaceuticals) and excluding special items

⁸ Investments in property, plant and equipment, and intangible assets, acquisitions

⁹ Proposal